The results showed that compared with platinum-based chemotherapy, pembrolizumab treatment significantly prolonged the OS of patients, suggesting that pembrolizumab treatment was a reasonable treatment option for NSCLC patients with low PD-L1 TPS and without EGFR mutation or ALK translocation. This evidence concerns the gene ALK and non-small cell lung carcinoma.